AIM Rules Compliance (Rule 26)

In accordance with AIM Rule 26, as stipulated by the London Stock Exchange, all AIM-quoted companies are required to disclose certain information on their corporate website.

In compliance with this rule, IS Pharma plc (incorporated in England & Wales registered number 3337415) has provided the following information on this site.

Shareholdings

As at 25 April 2008, the following significant shareholders of 3% or more of the ordinary share capital of the Company had been notified to the Company:

	No. of Ordinary Shares	% of issued share capital
Close Investments Limited	3,067,706	10.0%
Chase Nominees Limited	1,834,116	6.0%
ISIS	1,822,000	5.9%
Rathbones	1,821,597	5.9%
Noble Fund Managers Limited	1,815,330	5.9%
Barclays PLC	1,539,321	5.0%
MD Barnard & Co Limited	1,514,285	4.9%
Artemis	1,100,000	3.6%
Brewin Nominees Limited	1,076,687	3.5%
Pershing Keen Nominees Limited	962,307	3.1%
HSBC Nominees Limited	928,571	3.0%

As at 25 April 2008 6.9% (held by Directors and Acorus vendors) of the issued share capital was not in public hands.

The Company’s authorised and issued share capital is 40,000,000 and 30,754,404 70p ordinary shares respectively.

Restrictions on transfer of AIM securities

Pursuant to a lock-in agreement between the Company, Peter Murray, Stephen Jones, Geoff McMillan, Timothy Wright, Nigel Goldsmith, John Gregory and Ann Hardy (the “Locked-In Shareholders”) arising from the acquisition of Acorus Therapeutics Limited, the Locked-In Shareholders have undertaken not to dispose of any of their Ordinary Shares before 8 May 2008 with orderly marketing arrangements applying for a further 12 months.

The information above was updated on 30 May 2008.

For further information regarding IS Pharma's Rule 26 compliance please contact enquiries@ispharma.plc.uk

Admission Document

AIM Rule 26 Disclaimer

The attached Admission Document dated 5 April 2007 (the “Admission Document”) is being furnished for information purposes only in accordance with Rule 26 of the AIM Rules for Companies.

The Admission Document does not constitute an offer to sell or an invitation to purchase ordinary shares and/or other securities in IS Pharma PLC (the “Company”) in any jurisdiction and is not intended to form the basis of any investment decision or any other decision concerning the Company, its ordinary shares and/or other securities. The ordinary shares have not been nor will they be, registered under the US Securities Act of 1933, as amended, or under the securities laws of any state of the United States or under the applicable securities laws of Australia, the Republic of South Africa, New Zealand, Japan or Canada. Subject to certain exceptions, the ordinary shares may not directly or indirectly be offered or sold, in the United States, Australia, the Republic of South Africa, New Zealand, Japan or Canada or for the benefit of any US person (as defined under Regulation S under the Securities Act).

The Admission Document may not be distributed or reproduced without the prior written consent of the Company.

While the information provided in the Admission Document was believed to be accurate as of 25 April 2007, the Company and its Directors do not make any representations or warranties, express or implied, nor do they accept any responsibility or liability, as to the accuracy or completeness of such information. Nothing contained within the Admission Document is or should be relied upon as a promise or representation as to the future performance or prospects of the Company. The information provided in the Admission Document only speaks as of 5 April 2007 and the Company and its Directors expressly disclaim any obligation to provide any updates to the information contained in the Admission Document.

Circular

Proposed Acquisition of Speciality European Pharma International AG

Result of General Meeting held on 21 April 2008

Download the voting result PDF